Lamivudine or emtricitabine (XTC)/protease inhibitor dual therapy as a harm-reduction strategy in patients with tenofovir-related renal toxicity: A case–control study

References

• EACS Guidelines 2011. European AIDS Clinical Society. Available at: www.europeanaidsclinicalsociety.org/index.php?option = com_content&view = article&id =59:eacsguidelines&catid =37:guidelines&Itemid =41 (accessed 10 January 2012).
   Google Scholar
• Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Niño MD, Izquierdo MC, Poveda J, . Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011;2011: 354908.
   PubMedGoogle Scholar
• Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, Mayer K, . Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One 2011;6:e23688.
   PubMed Web of Science ®Google Scholar
• Crane HM, Grunfeld C, Willig JH, Mugavero MJ, Van Rompaey S, Moore R, . Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS 2011;25:185–95.
   PubMed Web of Science ®Google Scholar
• Saumoy M, Ordoñez-Llanos J, Martínez E, Barragán P, Ribera E, Bonet R, .; Bicombo-met Substudy Team. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir. Antivir Ther 2011;16:459–68.
   PubMed Web of Science ®Google Scholar
• Girard PM, Cabié A, Michelet C, Verdon R, Katlama C, Mercié P, . A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients. J Antimicrob Chemother 2009;64:126–34.
   PubMed Web of Science ®Google Scholar
• Calin R, Schneider L, Simon A, Peytavin G, Wirden M, Tubiana R, . Raltegravir/etravirine regimen in virologically suppressed HIV-1-infected patients. Abstract PE7.9/1. 13^th European AIDS Conference, Belgrade, Serbia, October 12–15, 2011.
   Google Scholar
• Nozza S, Galli L, Antinori A, Di Pietro M, Tommasi C, Zaccarelli M, . Maraviroc 150 mg QD plus lopinavir/ritonavir, a NRTI-sparing regimen for naïve patients: preliminary 48-weeks results. Abstract CDB325. 6^th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17–20, 2011.
   Google Scholar
• Portsmouth S, Craig C, Mills A, Mildvan D, Podzamczer G, Fätkenheuer G, . 48-week results of a dual-therapy regimen of once-daily maraviroc (MVC) 150 mg in combination with ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine/tenofovir (FTC/TDF) + ATV/r in treatment-naïve (TN) patients infected with CCR5-tropic HIV. Abstract TUAB0103. 6^th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17–20, 2011.
   Google Scholar
• Tyrer M, Swaden L, Marshall NJ, Johnson M. Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy. J Int AIDS Soc 2010;13(Suppl 4):P51.
   PubMed Web of Science ®Google Scholar
• Bernardino JI, Vergas J, Tellez MJ, Estrada V, Pérez-Cecilia E, Perez-Valero I, . Dual therapy with darunavir/ritonavir and etravirine in clinical practice: an NRTI-sparing strategy in ART experienced patients. Abstract CDB356. 6^th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17–20, 2011.
   Google Scholar
• Capetti AF, Piconi S, Landonio S, Rizzardini G, Perno CF. Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection? J Acquir Immune Defic Syndr 2009;50:233–4.
   PubMed Web of Science ®Google Scholar
• Allavena C, Mounoury O, Rodallec A, Reliquet V, Billaud E, Raffi F. Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population. HIV Clin Trials 2009;10:337–40.
   PubMed Web of Science ®Google Scholar
• Grant A, Kamuntu Y, Read P, Kulasegaram R. Switching to a ‘nuke-sparing’ raltegravir/atazanavir combination: an individualized approach. J Int AIDS Soc 2010;13(Suppl 4):P33.
   PubMed Web of Science ®Google Scholar
• Taiwo B, Zheng S, Gallien S, Matining R, Kuritzkes D, Wilson C, . Results from a single arm study of DRV/rtv + RAL in treatment-naïve HIV-1-infected patients (ACTG A5262). Abstract 551. 18^th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, February 27–March 2, 2011.
   Google Scholar
• Tsukada K, Nishijima T, Gatanaga H, Kanaya F, Kikuchi Y, Oka S. Efficacy of NRTI-sparing regimen of raltegravir plus boosted darunavir in NRTI intolerant patients. Abstract CDB357. 6^th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17–20, 2011.
   Google Scholar
• Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, . Lopinavir/ritonavir (LPV/r) combined with raltegravir (RAL) demonstrated similar antiviral efficacy and safety as LPV/r combined with tenofovir disoproxil fumarate/emtricitabine (FTC/TDF) in treatment-naïve HIV-1-infected subjects: PROGRESS 48 week result. Abstract MOAB0101. 18^th International AIDS Conference, Vienna, Austria, July 8–23, 2010.
   Google Scholar
• Ofotokun I, Sheth AN, Easley KA, Shenvi N, Rivas M, White K, . Switching antiretroviral therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients is safe and well tolerated (the KITE Study). Abstract CDB272. 6^th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17–20, 2011.
   Google Scholar
• Bedimo R, Drechsler H, Turner D, Moore T, Ghormley J, Jain M, . RADAR study: raltegravir combined with boosted darunavir has similar safety and antiviral efficacy as tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naïve patients. Abstract MOPE214. 6^th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17–20, 2011.
   Google Scholar
• Kozal MJ, Lupo S, DeJesus E, Molina JM, McDonald C, Raffi F, . The SPARTAN study: a pilot study to assess the safety and efficacy of an investigational NRTI- and RTV-sparing regimen of atazanavir (ATV) experimental dose of 300 mg BID plus raltegravir (RAL) 400 mg BID (ATV + RAL) in treatment-naïve HIV-infected subjects. Abstract THLBB204. 18^th International AIDS Conference, Vienna, Austria, July 8–23, 2010.
   Google Scholar
• Andrade R, Villareal-Williams E, Mall M, Shillington A, Pasley M, Trinh R, . A pilot study: lopinavir/ritonavir (LPV/r) plus lamivudine (3TC) as dual agents in antiretroviral (ARV) naïve HIV-infected subjects (the LOREDA study). Abstract CDB354. 6^th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17–20, 2011.
   Google Scholar
• De Luca A, Doino M, Fabbiani M, Bracciale L, Ciccarelli N, Colafigli M, . Treatment simplification to atazanavir/ritonavir plus lamivudine QD in patient on two NRTIs plus atazanavir/ritonavir with optimal virologic control: 48 weeks safety and efficacy result from a pilot study (ATazanavir and LAmivudine Simplification study). Abstract CDB357. 6^th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17–20, 2011.
   Google Scholar
• Nachega JB, Mugavero MJ, Zeier M, Vitória M, Gallant JE. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient Prefer Adherence 2011;5: 57–67.
   PubMed Web of Science ®Google Scholar
• Taburet AM, Piketty C, Chazallon C, Vincent I, Gérard L, Calvez V, .; ANRS Protocol 107 Puzzle 2 Investigators. Interactions between atazanavir–ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004;48:2091–6.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Nóvoa S, Morello J, Barreiro P, Maida I, García-Gascó P, Vispo E, . Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. AIDS Res Hum Retroviruses 2008;24:821–5.
   PubMed Web of Science ®Google Scholar
• Yoshino M, Yagura H, Kushida H, Yonemoto H, Bando H, Ogawa Y, . Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation. J Infect Chemother 2012;18:169–74.
   PubMed Web of Science ®Google Scholar